Research programme: muscarinic M2 receptor antagonists - Innoviva

Drug Profile

Research programme: muscarinic M2 receptor antagonists - Innoviva

Alternative Names: Overactive bladder therapeutics - Innoviva; THRX-326151

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Theravance
  • Developer Innoviva
  • Class Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Muscarinic M2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 10 Sep 2007 Preclinical trials in Overactive bladder in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top